Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • The Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

SEC Filings

Investors

Investors

  • Overview
  • News Releases
  • The Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • SEC Filings

  • Overview
Filter Filings:
Date Form Description Docs XBRL Pages
02/18/11 SC 13D/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities HTML PDF 6
02/16/11 D Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act HTML PDF 5
02/14/11 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-10.26
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF 102
02/14/11 SC 13D/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities HTML PDF 11
02/10/11 8-K Current report filing
Related Documents
EX-10.1
EX-10.2
EX-10.3
EX-99
HTML PDF 45
02/10/11 4 Statement of changes in beneficial ownership of securities HTML PDF 2
02/10/11 4 Statement of changes in beneficial ownership of securities HTML PDF 2
02/10/11 4 Statement of changes in beneficial ownership of securities HTML PDF 2
02/10/11 4 Statement of changes in beneficial ownership of securities HTML PDF 2
01/31/11 NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT HTML PDF 4
RSS
  • << Previous
  • 1...
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • ...96
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Feb 23, 2026

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Read More...
Feb 9, 2026

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Read More...
Feb 2, 2026

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Read More...
Copyrights © 2026 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap